Friday, July 10, 2026

Drug profile · INN

clomiphene citrate

clomiphene citrate (CLOMIPHENE CITRATE) is a estrogen receptor alpha modulator. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — clomiphene citrate
US status
approved
Class
Route
ORAL
Patents
0
Programs
2
Data quality
0.84

Quick answer

clomiphene citrate (CLOMIPHENE CITRATE) is a estrogen receptor alpha modulator. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN clomiphene citrate
Brand CLOMIPHENE CITRATE
Mechanism Estrogen receptor alpha modulator
Target Estrogen receptor
Route ORAL
Formulation TABLET

Mechanism of action

Estrogen receptor alpha modulator

Primary target: Estrogen receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Z171100001017104 Phase 2 · Universal Integrated · Anovulatory Infertility
  2. clomiphene citrate Unknown · Ultragenyx UK · Hyperinsulinism

Related & competitor drugs

  1. estradiol Estrogen receptor alpha agonist
  2. estradiol valerate Estrogen receptor alpha agonist
  3. estrogens, conjugated synthetic a Estrogen receptor agonist
  4. estropipate Estrogen receptor alpha agonist
  5. ethinyl estradiol Estrogen receptor alpha agonist
  6. fulvestrant Antineoplastic and immunomodulating agents (L02)

Frequently asked questions

What is clomiphene citrate?

clomiphene citrate (CLOMIPHENE CITRATE) is a estrogen receptor alpha modulator. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for clomiphene citrate?

CLOMIPHENE CITRATE is a marketed brand name for clomiphene citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of clomiphene citrate?

clomiphene citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.